{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:17:10Z","timestamp":1790864230745,"version":"4.1.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Hepatocellular carcinoma (HCC) is by far the leading malignant indication for liver transplantation (LT). Few other malignancies, including cholangiocellular carcinoma (CCC), metastases from neuroendocrine tumors (NET), and sarcomas of the liver (LSAR), also are commonly accepted indications for LT. However, there is limited information on their outcome after LT.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Graft and patient survival in 14,623 LTs performed in patients with hepatocellular carcinoma, CCC, NET, and LSAR from 1988 to 2017 and reported to the Collaborative Transplant Study were analyzed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The study group consisted of 13,862 patients who had HCC (94.8%), 498 (3.4%) who had CCC, 100 (0.7%) who had NET, and 163 (1.1%) who had LSAR. CCC patients showed a 5-year graft survival rate of 32.1%, strikingly lower than the 63.2% rate in HCC, 51.6% rate in NET, and 64.5% rate in LSAR patients (<jats:italic>P<\/jats:italic> &amp;lt; 0.001 for all vs. CCC). Multivariable Cox regression analysis revealed a significantly higher risk of graft loss and death due to cancer during the first five post-transplant years in CCC vs. HCC patients (HR 1.77 and 2.56; <jats:italic>P<\/jats:italic> &amp;lt; 0.001 for both). The same risks were increased also in NET and LSAR patients but did not reach statistical significance.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Among patients with rare malignant indications for LT, CCC patients showed significantly impaired graft as well as patient survival compared to HCC patients. The observed differences might challenge traditional decision-making processes for LT indication and palliative treatment in specific hepatic malignancies.<\/jats:p>","DOI":"10.3389\/fsurg.2021.678392","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T05:21:30Z","timestamp":1638508890000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Rare Malignant Indications for Liver Transplantation: A Collaborative Transplant Study Report"],"prefix":"10.3389","volume":"8","author":[{"given":"Philipp","family":"Houben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Schimmack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"D\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianeb","family":"Mehrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caner","family":"S\u00fcsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jhep.2012.04.015","article-title":"Evolution of indications and results of liver transplantation in Europe. A report from the European liver transplant registry (ELTR)","volume":"57","author":"Adam","year":"2012","journal-title":"J Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1097\/TP.0000000000002970","article-title":"Differential influence of donor age depending on the indication for liver transplantation-a collaborative transplant study report","volume":"104","author":"Houben","year":"2020","journal-title":"Transplantation."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.ejso.2019.07.024","article-title":"Liver transplantation for unresectable malignancies: beyond hepatocellular carcinoma","volume":"45","author":"Amer","year":"2019","journal-title":"Eur J Surg Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.soc.2013.10.006","article-title":"Hepatocellular carcinoma: diagnosis, management, and prognosis","volume":"23","author":"Page","year":"2014","journal-title":"Surg Oncol Clin N Am."},{"key":"B5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5009\/gnl15568","article-title":"Cholangiocarcinoma: current knowledge and new developments","volume":"11","author":"Blechacz","year":"2017","journal-title":"Gut Liver."},{"key":"B6","doi-asserted-by":"publisher","first-page":"12211","DOI":"10.3748\/wjg.v21.i43.12211","article-title":"Gallbladder carcinoma: prognostic factors and therapeutic options","volume":"21","author":"Goetze","year":"2015","journal-title":"World J Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1097\/00007890-200004270-00019","article-title":"Liver transplantation for cholangiocarcinoma: results in 207 patients","volume":"69","author":"Meyer","year":"2000","journal-title":"Transplantation."},{"key":"B8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S0002-9610(05)80696-8","article-title":"Is liver transplantation indicated for cholangiocarcinoma?","volume":"166","author":"Goldstein","year":"1993","journal-title":"Am J Surg."},{"key":"B9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1055\/s-2004-828896","article-title":"Liver transplantation for unresectable perihilar cholangiocarcinoma","volume":"24","author":"Heimbach","year":"2004","journal-title":"Semin Liver Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/jcm9051353","article-title":"Cholangiocarcinoma as an indication for liver transplantation in the era of transplant oncology","volume":"9","author":"Gringeri","year":"2020","journal-title":"J Clin Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.surg.2018.10.024","article-title":"What is transplant oncology?","volume":"165","author":"Hibi","year":"2019","journal-title":"Surgery."},{"key":"B12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.trre.2013.01.004","article-title":"The collaborative transplant study registry","volume":"27","author":"Opelz","year":"2013","journal-title":"Transplant Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/lt.24975","article-title":"Con: liver transplantation for expanded criteria malignant diseases","volume":"24","author":"Schaefer","year":"2018","journal-title":"Liver Transpl."},{"key":"B14","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1097\/TP.0b013e318281b902","article-title":"Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation\u2013the European liver transplant registry experience","volume":"95","author":"Orlando","year":"2013","journal-title":"Transplantation."},{"key":"B15","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/jso.24979","article-title":"Primary liver sarcomas in the modern era: resection or transplantation?","volume":"117","author":"Konstantinidis","year":"2018","journal-title":"J Surg Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/lt.25737","article-title":"Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis","volume":"26","author":"De Martin","year":"2020","journal-title":"Liver Transpl."},{"key":"B17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000347207","article-title":"Liver transplantation for perihilar cholangiocarcinoma","volume":"31","author":"Gores","year":"2013","journal-title":"Dig Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.hpb.2015.10.001","article-title":"Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database","volume":"18","author":"Vilchez","year":"2016","journal-title":"HPB."},{"key":"B19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Darwish Murad","year":"2012","journal-title":"Gastroenterology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/SLA.0000000000003801","article-title":"Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma","volume":"273","author":"Cambridge","year":"2021","journal-title":"Annals of Surgery."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/TP.0000000000003212","article-title":"Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: working group report from the ilts transplant oncology consensus conference","volume":"104","author":"Sapisochin","year":"2020","journal-title":"Transplantation."},{"key":"B22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer."},{"key":"B23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000365781","article-title":"Chemotherapy and targeted therapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"60","author":"Eckel","year":"2014","journal-title":"Chemotherapy."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jhep.2011.11.027","article-title":"Futility and rationing in liver retransplantation: when and how can we say no?","volume":"56","author":"Biggins","year":"2012","journal-title":"J Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1111\/ajt.13831","article-title":"The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors","volume":"16","author":"Mazzaferro","year":"2016","journal-title":"Am J Transplant."},{"key":"B26","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jhep.2007.07.004","article-title":"Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?","volume":"47","author":"Mazzaferro","year":"2007","journal-title":"J Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/archsurg.2011.186","article-title":"Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database","volume":"146","author":"Gedaly","year":"2011","journal-title":"Arch Surg."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1097\/TP.0000000000000723","article-title":"Variable use of model for end-stage liver disease exception points in patients with neuroendocrine tumors metastatic to the liver and its impact on patient outcomes","volume":"99","author":"Nobel","year":"2015","journal-title":"Transplantation."},{"key":"B29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/SLA.0b013e31828ee17c","article-title":"Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study","volume":"257","author":"Le Treut","year":"2013","journal-title":"Ann Surg."},{"key":"B30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/TP.0000000000001603","article-title":"Hepatic epithelioid hemangioendothelioma and adult liver transplantation: proposal for a prognostic score based on the analysis of the ELTR-ELITA registry","volume":"101","author":"Lai","year":"2017","journal-title":"Transplantation."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1002\/cncr.22225","article-title":"Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy","volume":"107","author":"Mehrabi","year":"2006","journal-title":"Cancer."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/apt.15253","article-title":"Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"49","author":"Grigg","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/SLA.0000000000004280","article-title":"mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors","volume":"272","author":"Schnitzbauer","year":"2020","journal-title":"Ann Surg."},{"key":"B34","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/SLA.0b013e3182823957","article-title":"Liver transplantation for nonresectable liver metastases from colorectal cancer","volume":"257","author":"Hagness","year":"2013","journal-title":"Ann Surg."},{"key":"B35","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/SLA.0000000000003404","article-title":"Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases","volume":"271","author":"Dueland","year":"2020","journal-title":"Ann Surg."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1315","DOI":"10.1634\/theoncologist.2018-0675","article-title":"Meta-Analysis of randomized clinical trials comparing active treatment with placebo in metastatic neuroendocrine tumors","volume":"24","author":"Capdevila","year":"2019","journal-title":"Oncologist."},{"key":"B37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-Controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology."}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2021.678392\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T05:21:34Z","timestamp":1638508894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2021.678392\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":37,"alternative-id":["10.3389\/fsurg.2021.678392"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2021.678392","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,3]]},"article-number":"678392"}}